Translational research in oncolytic measles virotherapy: Early discoveries and future steps

Future Microbiology

Volumn 6, Issue 2, 2011, Pages 125-128

  Msaouel, Pavlos ^a   Opyrchal, Mateusz ^b   Galanis, Evanthia ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b MAYO CLINIC   (United States)

Author keywords

cancer therapeutics; engineering; measles virus; oncolytic viruses; radiovirotherapy; virotherapy

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; MEASLES VACCINE; ONCOLYTIC MEASLES CARCINOEMBRYONIC ANTIGEN VIRUS; ONCOLYTIC MEASLES SODIUM IODIDE SYMPORTER VIRUS; ONCOLYTIC VIRUS; PACLITAXEL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; HUMAN; INNATE IMMUNITY; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MULTIPLE MYELOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN;

HUMANS; MORBILLIVIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSLATIONAL RESEARCH;

MEASLES VIRUS;

EID: 79952404748     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.170     Document Type: Review

References (36)

1. Hendrix RW, Lawrence JG, Hatfull GF, Casjens S: The origins and ongoing evolution of viruses. Trends Microbiol. 8, 504-508 (2000).
2. Bazin H: The Eradication of Smallpox : Edward Jenner and the First and Only Eradication of a Human Infectious Disease. Academic Press, CA, USA (2000).
3. Liu TC, Galanis E, Kirn D: Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4(2), 101-117 (2007). (Pubitemid 46189539)
4. Hernandez SA: Observacion de un caso de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, post-sarampion. Arch. Cubanos Cancer 8, 26-31 (1949).
5. Tatsuo H, Ono N, Tanaka K, Yanagi Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature 406(6798), 893-897 (2000). (Pubitemid 30664265)
6. Griffin DE, Pan CH: Measles: Old vaccines, new vaccines. Curr. Top. Microbiol. Immunol. 330, 191-212 (2009).
7. Dorig RE, Marcil A, Chopra A, Richardson CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75(2), 295-305 (1993). (Pubitemid 23320293)
8. Anderson BD, Nakamura T, Russell SJ, Peng KW: High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64(14), 4919-4926 (2004). (Pubitemid 38924538)
9. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M: Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40(2-4), 109-123 (2003). (Pubitemid 36959821)
10. Blechacz B, Russell SJ: Measles virus as an oncolytic vector platform. Curr. Gene Ther. 8(3), 162-175 (2008).
11. Russell SJ, Peng KW: Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 330, 213-241 (2009).
12. Phuong LK, Allen C, Peng KW et al.: Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63(10), 2462-2469 (2003). (Pubitemid 36605184)
13. Radecke F, Spielhofer P, Schneider H et al.: Rescue of measles viruses from cloned DNA. EMBO J. 14(23), 5773-5784 (1995).
14. Nakamura T, Peng KW, Harvey M et al.: Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23(2), 209-214 (2005). (Pubitemid 40255331)
15. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R: Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 66(15), 7694-7700 (2006). (Pubitemid 44289228)
16. Billeter MA, Naim HY, Udem SA: Reverse genetics of measles virus and resulting multivalent recombinant vaccines: Applications of recombinant measles viruses. Curr. Top. Microbiol. Immunol. 329, 129-162 (2009).
17. Hadac EM, Peng KW, Nakamura T, Russell SJ: Reengineering paramyxovirus tropism. Virology 329(2), 217-225 (2004). (Pubitemid 39423972)
18. Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R: Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106(7), 2287-2294 (2005). (Pubitemid 41510798)
19. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ: Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62(16), 4656-4662 (2002).
20. Dingli D, Peng KW, Harvey ME et al.: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103(5), 1641-1646 (2004). (Pubitemid 38268954)
21. Dingli D, Peng KW, Harvey ME et al.: Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem. Biophys. Res. Commun. 337(1), 22-29 (2005). (Pubitemid 41393753)
22. Fulci G, Breymann L, Gianni D et al.: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103(34), 12873-12878 (2006). (Pubitemid 44298654)
23. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW: Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res. 12(6), 1868-1875 (2006).
24. Kambara H, Saeki Y, Chiocca EA: Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res. 65(24), 11255-11258 (2005). (Pubitemid 41821678)
25. Mazzaferri EL, Kloos RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86(4), 1447-1463 (2001). (Pubitemid 32374886)
26. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW: Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 14(4), 324-333 (2007). (Pubitemid 46231926)
27. Msaouel P, Dispenzieri A, Galanis E: Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview. Curr. Opin. Mol. Ther. 11(1), 43-53 (2009).
28. Myers RM, Greiner SM, Harvey ME et al.: Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin. Pharmacol. Ther. 82(6), 700-710 (2007). (Pubitemid 350114828)
29. Myers R, Harvey M, Kaufmann TJ et al.: Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum. Gene Ther. 19(7), 690-698 (2008). (Pubitemid 352009918)
30. Galanis E, Hartmann LC, Cliby WA et al.: Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70(3), 875-882 (2010).
31. Prestwich RJ, Errington F, Diaz RM et al.: The case of oncolytic viruses versus the immune system: Waiting on the judgment of Solomon. Hum. Gene Ther. 20(10), 1119-1132 (2009).
32. Iankov ID, Blechacz B, Liu C et al.: Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther. 15(1), 114-122 (2007). (Pubitemid 46043656)
33. Mader EK, Maeyama Y, Lin Y et al.: Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 15(23), 7246-7255 (2009).
34. Ungerechts G, Springfeld C, Frenzke ME et al.: An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther. 15(11), 1991-1997 (2007). (Pubitemid 350011739)
35. Haralambieva I, Iankov I, Hasegawa K, Harvey M, Russell SJ, Peng KW: Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther. 15(3), 588-597 (2007).
36. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ: Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17(8), 550-558 (2010).